Organon & Co. (NYSE:OGN) Receives $12.50 Average PT from Analysts

Organon & Co. (NYSE:OGN) has earned an average rating of “Hold” from the seven brokerages that are presently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $12.50.

OGN has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d+)” rating on shares of Organon & Co. in a research report on Wednesday, October 8th. Morgan Stanley decreased their price target on Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 11th. JPMorgan Chase & Co. dropped their price objective on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating for the company in a report on Tuesday, November 11th. Finally, Piper Sandler lowered shares of Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 target price for the company. in a research note on Monday, October 27th.

Hedge Funds Weigh In On Organon & Co.

A number of institutional investors have recently modified their holdings of OGN. Envestnet Asset Management Inc. grew its stake in Organon & Co. by 25.3% in the first quarter. Envestnet Asset Management Inc. now owns 303,138 shares of the company’s stock worth $4,514,000 after purchasing an additional 61,228 shares in the last quarter. Victory Capital Management Inc. grew its position in shares of Organon & Co. by 81.7% during the 1st quarter. Victory Capital Management Inc. now owns 401,967 shares of the company’s stock worth $5,985,000 after buying an additional 180,689 shares in the last quarter. Allianz Asset Management GmbH increased its stake in shares of Organon & Co. by 15.2% during the first quarter. Allianz Asset Management GmbH now owns 1,276,249 shares of the company’s stock valued at $19,003,000 after buying an additional 167,958 shares during the period. Choreo LLC raised its holdings in shares of Organon & Co. by 13.9% in the first quarter. Choreo LLC now owns 23,905 shares of the company’s stock valued at $356,000 after acquiring an additional 2,917 shares in the last quarter. Finally, AE Wealth Management LLC raised its holdings in shares of Organon & Co. by 10.9% in the first quarter. AE Wealth Management LLC now owns 167,532 shares of the company’s stock valued at $2,495,000 after acquiring an additional 16,476 shares in the last quarter. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Trading Down 1.8%

OGN stock opened at $7.07 on Friday. Organon & Co. has a twelve month low of $6.18 and a twelve month high of $17.23. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of 3.68, a price-to-earnings-growth ratio of 1.54 and a beta of 0.59. The company has a quick ratio of 1.20, a current ratio of 1.75 and a debt-to-equity ratio of 9.69. The firm’s fifty day simple moving average is $8.82 and its two-hundred day simple moving average is $9.30.

Organon & Co. (NYSE:OGN) last released its earnings results on Monday, November 10th. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.08. The firm had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a net margin of 7.95% and a return on equity of 143.47%. During the same quarter last year, the business earned $1.38 EPS. Organon & Co. has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 11th. Shareholders of record on Thursday, November 20th will be given a $0.02 dividend. This represents a $0.08 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Thursday, November 20th. Organon & Co.’s payout ratio is 4.17%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.